DR. STANLEY RUSSEL PILLEMER, MD
Osteopathic Medicine at Coastal Hwy, Ocean City, MD
License number
Maryland D0031644
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
7408 Coastal Hwy, Ocean City, MD 21842
14408 Quietwood Ter, Gaithersburg, MD 20878
14408 Quietwood Ter, Gaithersburg, MD 20878
Phone
(410) 524-0075
(301) 762-2215
(301) 762-2215
Professional information
Stanley R Pillemer, Gaithersburg MD
Specialties:
Internal Medicine, Rheumatology
Work:
American Biopharma Corporation
PO Box 84091, Gaithersburg, MD 20883 Clin. Research & Product Safety Macrogenics
1500 E Gude Dr, Rockville, MD 20850
PO Box 84091, Gaithersburg, MD 20883 Clin. Research & Product Safety Macrogenics
1500 E Gude Dr, Rockville, MD 20850
Dr. Stanley R Pillemer, Ocean City MD - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
7408 Coastal Hwy, Ocean City 21842
(410) 524-0075 (Phone)
(410) 524-0075 (Phone)
Certifications:
Internal Medicine, 1981, Rheumatology, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of The Witwatersrand/Faculty of Health Sciences
University of The Witwatersrand/Faculty of Health Sciences
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US Patent:
2008009, Apr 24, 2008
Filed:
Jun 14, 2007
Appl. No.:
11/763434
Inventors:
Scott Koenig - Rockville MD, US
Ronald Wilder - Rockville MD, US
Ezio Bonvini - Rockville MD, US
Leslie Johnson - Darnestown MD, US
Stanley Pillemer - North Potomac MD, US
Ronald Wilder - Rockville MD, US
Ezio Bonvini - Rockville MD, US
Leslie Johnson - Darnestown MD, US
Stanley Pillemer - North Potomac MD, US
Assignee:
MacroGenics, Inc. - Rockville MD
International Classification:
A61K 39/395, A61P 1/00, A61P 17/06, A61P 19/02, A61P 25/00, A61P 3/10, A61P 35/00, A61P 37/06
US Classification:
424133100, 424144100, 424154100
Abstract:
The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.